AL amyloidosis

Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis

George T, Staron A, Burks EJ, Szalat RE, Sanchorawala V

British Journal of Haematology208(6):2252-2255DOI: Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosisPubMed: Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis

Hepatic response criteria in light chain amyloidosis: a multicenter validation study

Muchtar E, Palladini G, Schonland S, …, Szalat R, …, Gertz MA

HaematologicaDOI: Hepatic response criteria in light chain amyloidosis: a multicenter validation studyPubMed: Hepatic response criteria in light chain amyloidosis: a multicenter validation study

Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X Deficiency

Cetin O, Staron A, Teodorescu P, Sloan JM, Sanchorawala V, Szalat R

American Journal of Hematology100(12):2416-2420DOI: Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X DeficiencyPubMed: Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X Deficiency

Febrile neutropenia in patients with Duffy-null–associated neutrophil counts and multiple myeloma or AL amyloidosis

Abdallah M, Arters F, Patel J, …, Szalat R

Blood Advances8(23):5935-5938DOI: Febrile neutropenia in patients with Duffy-null–associated neutrophil counts and multiple myeloma or AL amyloidosisPubMed: Febrile neutropenia in patients with Duffy-null–associated neutrophil counts and multiple myeloma or AL amyloidosis

Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

Muchtar E, Wisniowski B, Geyer S, …, Szalat R, …, Gertz MA

JAMA Oncology10(10):1362DOI: Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisPubMed: Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

Muchtar E, Dispenzieri A, Wisniowski B, …, Szalat R, …, Gertz MA

Journal of Clinical Oncology41(7):1393-1403DOI: Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisPubMed: Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes

Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V

Haematologica108(6):1680-1684DOI: Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomesPubMed: Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes

Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study

Gustine JN, Staron A, Szalat RE, …, Sanchorawala V

American Journal of Hematology97(9):1189-1199DOI: Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal studyPubMed: Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study

Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis

Acevedo J, Doros G, Szalat R, Sanchorawala V

Clinical Lymphoma Myeloma and Leukemia21(6):425-426DOI: Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL AmyloidosisPubMed: Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis

Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab

Szalat RE, Gustine J, Sloan JM, Edwards CV, Sanchorawala V

American Journal of Hematology97(1):79-89DOI: Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumabPubMed: Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab

Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V

Leukemia35(3):916-919DOI: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosisPubMed: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes

Smith J, Samur M, Talluri S, …, Szalat R

Blood146(Supplement 1):3923-3923DOI: Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes

Bone marrow plasma cells and immune microenvironment transcriptomic architecture in AL amyloidosis during daratumumab based therapy

Szalat R, Talluri S, Wong S, Morgan G, Sanchorawala V, Munshi N, et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS31:S176-S176

Clinical Characteristics and Therapeutic Response of Patients with Heavy Chain (AH) and Heavy and Light Chain (AHL) Amyloidosis

Li KY, Staron A, Sanchorawala V, Szalat RE

Blood144(Supplement 1):3303-3303DOI: Clinical Characteristics and Therapeutic Response of Patients with Heavy Chain (AH) and Heavy and Light Chain (AHL) Amyloidosis

Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency

Cetin O, Teodorescu P, Staron A, Sanchorawala V, Szalat RE

Blood144(Supplement 1):4671-4671DOI: Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency

Composition and Dynamic Evolution of the Bone Marrow Microenvironment in AL Amyloidosis during Daratumumab Based Therapy

Szalat RE, Talluri S, Royer CM, Wong S, Morgan G, Sanchorawala V, Samur MK, Munshi NC

Blood142(Supplement 1):3416-3416DOI: Composition and Dynamic Evolution of the Bone Marrow Microenvironment in AL Amyloidosis during Daratumumab Based Therapy

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Muchtar E, Palladini G, Schonland S, …, Szalat RE, …, Gertz MA

Blood142(Supplement 1):3411-3411DOI: Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab

Staron A, Burks EJ, Szalat RE, Sanchorawala V

Blood142(Supplement 1):3405-3405DOI: Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Muchtar E, Dispenzieri A, Wisniowski B, …, Szalat R, …, Gertz MA

Blood138(Supplement 1):2720-2720DOI: Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Muchtar E, Wisniowski B, Palladini G, …, Szalat R, …, Gertz MA

Blood138(Supplement 1):2721-2721DOI: Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis

Muchtar E, Wisniowski B, Palladini G, …, Szalat R, …, Gertz M

Clinical Lymphoma Myeloma and Leukemia21:S23-S24DOI: OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis

Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab

Szalat R, Gustine J, Sloan JM, Sanchorawala V

Blood138(Supplement 1):2734-2734DOI: Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Acevedo J, Doros G, Szalat R, Sloan JM, Sarosiek S, Sanchorawala V

Blood134(Supplement_1):5447-5447DOI: Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center